TY - JOUR AU - Drake, C. G. AU - Lipson, E. J. AU - Brahmer, J. R. PY - 2014 DA - 2014// TI - Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer JO - Nat Rev Clin Oncol VL - 11 UR - https://doi.org/10.1038/nrclinonc.2013.208 DO - 10.1038/nrclinonc.2013.208 ID - Drake2014 ER - TY - JOUR AU - Camacho, L. H. PY - 2015 DA - 2015// TI - CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations JO - Cancer Med VL - 4 UR - https://doi.org/10.1002/cam4.371 DO - 10.1002/cam4.371 ID - Camacho2015 ER - TY - JOUR AU - Brahmer, J. R. AU - Lacchetti, C. AU - Schneider, B. J. AU - Atkins, M. B. AU - Brassil, K. J. AU - Caterino, J. M. PY - 2018 DA - 2018// TI - Management of Immune-Related Adverse Events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2017.77.6385 DO - 10.1200/JCO.2017.77.6385 ID - Brahmer2018 ER - TY - JOUR AU - Puzanov, I. AU - Diab, A. AU - Abdallah, K. AU - Bingham, C. O. AU - Brogdon, C. AU - Dadu, R. PY - 2017 DA - 2017// TI - Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group JO - J Immunother Cancer VL - 5 UR - https://doi.org/10.1186/s40425-017-0300-z DO - 10.1186/s40425-017-0300-z ID - Puzanov2017 ER - TY - STD TI - Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Davies M, et al. Management of Immunotherapy-Related Toxicities (immune checkpoint inhibitor-related toxicities) version 2.2018. NCCN. 2018 [updated 2018 Aug 19]. https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf UR - https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf ID - ref5 ER - TY - JOUR AU - Mir, R. AU - Shaw, H. M. AU - Nathan, P. D. PY - 2017 DA - 2017// TI - Immunosuppressive agents and their role in managing immunotherapy toxicities in melanoma JO - Clin Ski Cancer VL - 2 UR - https://doi.org/10.1016/j.clsc.2017.07.001 DO - 10.1016/j.clsc.2017.07.001 ID - Mir2017 ER - TY - JOUR AU - Rotz, S. J. AU - Leino, D. AU - Szabo, S. AU - Mangino, J. L. AU - Turpin, B. K. AU - Pressey, J. G. PY - 2017 DA - 2017// TI - Severe cytokine release syndrome in a patient receiving PD-1-directed therapy JO - Pediatr Blood Cancer VL - 64 UR - https://doi.org/10.1002/pbc.26642 DO - 10.1002/pbc.26642 ID - Rotz2017 ER - TY - JOUR AU - Kim, S. T. AU - Tayar, J. AU - Trinh, V. A. AU - Suarez-Almazor, M. AU - Garcia, S. AU - Hwu, P. PY - 2017 DA - 2017// TI - Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series JO - Ann Rheum Dis VL - 76 UR - https://doi.org/10.1136/annrheumdis-2017-211560 DO - 10.1136/annrheumdis-2017-211560 ID - Kim2017 ER - TY - JOUR AU - Stroud, C. R. G. AU - Hegde, A. AU - Cherry, C. AU - Naqash, A. R. AU - Sharma, N. AU - Addepalli, S. PY - 2017 DA - 2017// TI - Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade JO - J Oncol Pharm Pract VL - 0 ID - Stroud2017 ER - TY - JOUR AU - Asnani, A. PY - 2018 DA - 2018// TI - Cardiotoxicity of immunotherapy: incidence, diagnosis, and Management JO - Curr Oncol Rep VL - 20 UR - https://doi.org/10.1007/s11912-018-0690-1 DO - 10.1007/s11912-018-0690-1 ID - Asnani2018 ER - TY - JOUR AU - Johnston, R. L. AU - Lutzky, J. AU - Chodhry, A. AU - Barkin, J. S. PY - 2009 DA - 2009// TI - Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab JO - Dig Dis Sci VL - 54 UR - https://doi.org/10.1007/s10620-008-0641-z DO - 10.1007/s10620-008-0641-z ID - Johnston2009 ER - TY - JOUR AU - Minor, D. R. AU - Chin, K. AU - Kashani-sabet, M. PY - 2009 DA - 2009// TI - Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis JO - Cancer Biother Radiopharm VL - 24 UR - https://doi.org/10.1089/cbr.2008.0607 DO - 10.1089/cbr.2008.0607 ID - Minor2009 ER - TY - JOUR AU - Doctor, P. AU - Sultan, A. AU - Syed, S. AU - Christen, W. AU - Bhat, P. AU - Foster, C. S. PY - 2010 DA - 2010// TI - Infliximab for the treatment of refractory scleritis JO - Br J Ophthalmol VL - 94 UR - https://doi.org/10.1136/bjo.2008.150961 DO - 10.1136/bjo.2008.150961 ID - Doctor2010 ER - TY - JOUR AU - Luke, J. J. AU - Lemons, J. M. AU - Karrison, T. G. AU - Pitroda, S. P. AU - Melotek, J. M. AU - Zha, Y. PY - 2018 DA - 2018// TI - Safety and clinical activity of Pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2017.76.2229 DO - 10.1200/JCO.2017.76.2229 ID - Luke2018 ER - TY - STD TI - McBride SM, Sherman EJ, Tsai CJ, Baxi SS, Aghalar J, Eng J, et al. A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC) [abstract]. J Clin Oncol. 2018;36(suppl; abstr 6009). http://abstracts.asco.org/214/AbstView_214_223041.html. UR - http://abstracts.asco.org/214/AbstView_214_223041.html ID - ref15 ER - TY - JOUR AU - Cuzzubbo, S. AU - Javeri, F. AU - Tissier, M. AU - Roumi, A. AU - Barlog, C. AU - Doridam, J. PY - 2017 DA - 2017// TI - Neurological adverse events associated with immune checkpoint inhibitors: review of the literature JO - Eur J Cancer VL - 73 UR - https://doi.org/10.1016/j.ejca.2016.12.001 DO - 10.1016/j.ejca.2016.12.001 ID - Cuzzubbo2017 ER - TY - STD TI - Scott TF, Frohman EM, De Seze J, Gronseth GS, Weinshenker BG. Evidence-based guideline: Clinical evaluation and treatment of transverse myelitis. Neurology 2011;77(24):2128 LP – 2122134. http://n.neurology.org/content/77/24/2128 ID - ref17 ER - TY - STD TI - Garcia CA, El-Ali A, Rath TJ, et al. Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases. J Immunother Cancer. 2018;6(83) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6117978/. UR - http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6117978/ ID - ref18 ER - TY - JOUR AU - Abbatucci, J. S. AU - Delozier, T. AU - Quint, R. AU - Roussel, A. B. D. PY - 1978 DA - 1978// TI - Radiation myelopathy of the cervical spinal cord: time, dose and volume factors JO - Int J Radiat Oncol Biol Phys VL - 4 UR - https://doi.org/10.1016/0360-3016(78)90144-X DO - 10.1016/0360-3016(78)90144-X ID - Abbatucci1978 ER - TY - JOUR AU - Kirkpatrick, J. P. AU - Kogel, A. J. AU - Schultheiss, T. E. PY - 2010 DA - 2010// TI - Radiation dose-volume effects in the spinal cord JO - Int J Radiat Oncol Biol Phys VL - 76 UR - https://doi.org/10.1016/j.ijrobp.2009.04.095 DO - 10.1016/j.ijrobp.2009.04.095 ID - Kirkpatrick2010 ER - TY - JOUR AU - Wong, C. S. AU - Dyk, J. AU - Milosevic, M. L. N. PY - 1994 DA - 1994// TI - Radiation myelopathy following single course of radiotherapy and retreatment JO - Int J Radiat Oncol Biol Phys VL - 30 UR - https://doi.org/10.1016/0360-3016(92)90943-C DO - 10.1016/0360-3016(92)90943-C ID - Wong1994 ER - TY - JOUR AU - Wong, C. S. AU - Fehlings, M. G. AU - Sahgal, A. PY - 2015 DA - 2015// TI - Pathobiology of radiation myelopathy and strategies to mitigate injury JO - Spinal Cord VL - 53 UR - https://doi.org/10.1038/sc.2015.43 DO - 10.1038/sc.2015.43 ID - Wong2015 ER -